Treatment and Management of Primary Biliary Cholangitis
All patients with PBC should be started on ursodeoxycholic acid (UDCA) at 13-15 mg/kg/day as first-line therapy, with biochemical response assessed at 12 months to determine if second-line agents are needed 1.
First-Line Treatment: UDCA
UDCA remains the gold standard and should be offered to all patients with PBC 1. The target dose of 13-15 mg/kg/day improves biochemical parameters and patient survival 2. At least 90% of patients should be receiving therapy at adequate dose or documented to be intolerant 1.
Baseline Assessment Requirements
Before initiating therapy:
- Abdominal ultrasound to exclude alternative causes of cholestasis (90% standard) 1
- Osteoporosis risk assessment (80% within 5 years standard) 1
- Document presence/absence of fatigue and pruritus (90% standard annually) 1
Assessing Treatment Response at 12 Months
Risk stratification using biochemical response indices is mandatory after 1 year of UDCA therapy 1. Approximately 40% of patients exhibit inadequate biochemical response 3, 4.
Treatment Goals by Risk Profile
- Optimal goal (lowest risk): Normalization of alkaline phosphatase (ALP) AND total bilirubin <0.6× upper limit of normal 5, 6
- Adequate response: Various validated criteria exist, but ALP normalization represents the improved therapeutic goal for high-risk patients 4
- High-risk patients: Those with elevated bilirubin >50 μmol/L or decompensated disease require hepatologist discussion for transplant consideration 1
Second-Line Therapies for Inadequate Responders
The therapeutic landscape has shifted significantly with obeticholic acid (OCA) withdrawn from availability 3. Current second-line options include:
FDA-Approved Second-Line Agents (2026)
- Elafibranor (conditional approval for non-cirrhotic patients) 3
- Seladelpar (conditional approval for non-cirrhotic patients) 3
Off-Label Options
- Fibrates (particularly bezafibrate): Improve biochemical parameters, elastographic findings, and have antipruritic effects 2, 5. Can be used in decompensated fibrotic patients 4
Important caveat: The newer PPAR agonists are approved only for patients without cirrhosis, making fibrates particularly valuable for advanced disease 3, 6.
Symptom Management
Pruritus
Bezafibrate, seladelpar, and IBAT inhibitors demonstrate significant therapeutic potential 4. This is critical as pruritus profoundly impacts quality of life.
Fatigue
- Fatigue has the biggest impact on patients and correlates with poor quality of life 1
- Patients with profound psychological distress from fatigue should be referred to psychological services 1
- Consider cognitive behavioral therapy approaches 1
Social Support
Recommend patient support groups (strong recommendation) including PBC Foundation, LIVErNorth, and Liver4Life 1.
Special Considerations
AIH-PBC Overlap Syndrome
- Recognized as rare 1
- Liver biopsy with expert clinicopathological assessment is required when suspected (90% standard) 1
- Consider in cholestatic patients with negative AMA or inadequate UDCA responders with elevated ALT and IgG 4
- Combined immunosuppressants for moderate-to-severe hepatitis 4
Monitoring Disease Progression
- Liver stiffness measurement is efficient for fibrotic monitoring 4
- Document response status and criteria used (80% standard) 1
- Early prediction at baseline and 1-month helps identify treatment-responsive patients earlier than the traditional "wait-to-fail" strategy 4
Common Pitfalls to Avoid
- Underdosing UDCA: Ensure 13-15 mg/kg/day, not weight-independent dosing
- Delayed response assessment: Must evaluate at 12 months, not waiting longer
- Missing overlap syndrome: Biopsy when biochemistry suggests AIH features
- Ignoring symptoms: Document fatigue and pruritus annually even if biochemistry improves
- Late transplant referral: Discuss with transplant hepatologist when bilirubin >50 μmol/L